06.07.2015 • News

Akzo to Sell Biomaterials Technology to Ashland

In a transaction set to close in the third quarter of this year, AkzoNobel has announced plans to sell its biomaterials technology to Ashland of the US.

The Dutch chemical producer said the business is in its early phase of commercialization, and the divestment plans follow a strategic review that determined it was not a good fit with the company’s portfolio.

The activities are focused on plant-based chemistry used to develop products for various applications, such as high performance beauty technologies.

“This transaction will enable us to focus on our core technology platforms of specialty surfactants and polymers and help reinforce our leadership position in both areas,” Akzo Nobel said.

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read